Andere talen Travere Therapeutics, Inc.

Aandelen

TVTX

US89422G1076

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,16 ^USD	+2,67%		+13,03%	-31,48%

24/04	CSL Vifor en Travere Therapeutics kondigen aan dat de Europese Commissie FILSPARI® (sparsentan) goedkeurt voor de behandeling van IgA-nefropathie	CI
03/04	Travere Therapeutics presenteert samenvattingen over Filspari® (Sparsentan) in Iga-nefropathie op het Wereldcongres voor Nefrologie en de American Nephrology Nurses Association	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Travere Therapeutics to Report First Quarter 2024 Financial Results	29/04
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI for the treatment of IgA Nephropathy	25/04
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	24/04
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy	24/04
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	24/04
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy	24/04
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	24/04
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International	04/04
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association	03/04
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	03/04
North American Morning Briefing : Stocks Set for -2-	28/03
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	13/03
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	13/03
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy	11/03
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)	11/03
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy	11/03
Travere Therapeutics to Present at Upcoming Investor Conferences	26/02
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy	26/02
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease	23/02
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy	23/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Travere Therapeutics, Inc.

Aandelen

TVTX

US89422G1076

Andere talen

Filters